Breast cancer affects up to one in 10 women in Western and industrialized countries and the total number of cases diagnosed are about 190,000 each year in the United States alone, with a considerable mortality rate of 40,000. This strongly motivates the development of more effective treatments. Results from recent epidemiological and experimental studies have revealed significant beneficial association between breast cancer and hydrophobic statin therapy. Nanoemulsions offer exciting new possibilities for better treatment strategies of hydrophobic compounds by improving the biodistribution, the circulation half-life, and by diminishing interactions with plasma proteins or other plasma constituents. In addition, they also offer the possibility for target-specific delivery and, importantly, the integration of multiple properties, e.g. to allow therapy and diagnostics with the same agent. In this project we propose to develop a unique theranostic and surface activatable nanoparticle platform, which can be applied for target-specific MRI and anti-tumor therapy of breast cancer. The nanoparticles are targeted to 1v23-expressing breast cancer cells via RGD-peptides, but are prevented from targeting 1v23-expressing cells in the circulation through the following strategy: When the nanoparticles circulate, the RGD-peptides are actively shielded by long PEG-chains to minimize their exposure to the angiogenic vasculature and the cells of the reticulo-endothelial system. Once the particles accumulate in the tumor interstitial space, the PEG-chains are cleaved off by matrix metalloproteinase-2 activity inside the tumor and the RGD-moieties become available to facilitate uptake by tumor cells. Full in vitro targeting and efficacy studies will be performed. In vivo, biodistribution and molecular imaging studies will be performed on mouse breast cancer models in order to evaluate targeting efficiency. Lastly, therapeutic efficacy will be investigated in the same mouse models. Extensive immunofluorescent, histological, and molecular biological techniques will be applied to evaluate the in vivo findings and to unravel the mechanism of action.
The specific aims are:
Aim 1 : To synthesize and characterize a surface-switching nanoemulsion platform for targeting, visualizing and treating breast cancer.
Aim 2 : To test the targeting efficacy and therapeutic potential of nanoemulsions in vitro on different cell types.
Aim 3 : To study the biodistribution and targeted 'trapping'of surface-switching nanoemulsions in a breast cancer mouse model via in vivo imaging.
Aim 4 : To conduct a therapy study where surface-switching nanoemulsions, that carry statins, are applied to a breast cancer mouse model.

Public Health Relevance

In this project we propose the development of a surface activatable nanoemulsion platform for the diagnosis and treatment of breast cancer. We will test the platform on breast cancer cells in vitro and mouse models in vivo, use magnetic resonance imaging and optical imaging to determine endpoints, and thoroughly investigate and validate targeting and therapeutic efficacy using traditional molecular biology and histological techniques. We expect that our overall approach will improve the diagnosis and treatment of breast cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA155432-03
Application #
8507620
Study Section
Clinical Molecular Imaging and Probe Development (CMIP)
Program Officer
Tandon, Pushpa
Project Start
2011-09-01
Project End
2016-07-31
Budget Start
2013-08-01
Budget End
2014-07-31
Support Year
3
Fiscal Year
2013
Total Cost
$330,610
Indirect Cost
$135,560
Name
Icahn School of Medicine at Mount Sinai
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
078861598
City
New York
State
NY
Country
United States
Zip Code
10029
Mulder, Willem J M; Jaffer, Farouc A; Fayad, Zahi A et al. (2014) Imaging and nanomedicine in inflammatory atherosclerosis. Sci Transl Med 6:239sr1
Hak, Sjoerd; Cebulla, Jana; Huuse, Else Marie et al. (2014) Periodicity in tumor vasculature targeting kinetics of ligand-functionalized nanoparticles studied by dynamic contrast enhanced magnetic resonance imaging and intravital microscopy. Angiogenesis 17:93-107
Pérez-Medina, Carlos; Abdel-Atti, Dalya; Zhang, Yachao et al. (2014) A modular labeling strategy for in vivo PET and near-infrared fluorescence imaging of nanoparticle tumor targeting. J Nucl Med 55:1706-11
Duivenvoorden, Raphaël; Tang, Jun; Cormode, David P et al. (2014) A statin-loaded reconstituted high-density lipoprotein nanoparticle inhibits atherosclerotic plaque inflammation. Nat Commun 5:3065
Kim, Yongtae; Lobatto, Mark E; Kawahara, Tomohiro et al. (2014) Probing nanoparticle translocation across the permeable endothelium in experimental atherosclerosis. Proc Natl Acad Sci U S A 111:1078-83
Lameijer, Marnix A; Tang, Jun; Nahrendorf, Matthias et al. (2013) Monocytes and macrophages as nanomedicinal targets for improved diagnosis and treatment of disease. Expert Rev Mol Diagn 13:567-80
Allijn, Iris E; Leong, Wei; Tang, Jun et al. (2013) Gold nanocrystal labeling allows low-density lipoprotein imaging from the subcellular to macroscopic level. ACS Nano 7:9761-70
Fay, Francois; Sanchez-Gaytan, Brenda L; Cormode, David P et al. (2013) Nanocrystal Core Lipoprotein Biomimetics for Imaging of Lipoproteins and Associated Diseases. Curr Cardiovasc Imaging Rep 6:45-54
Gianella, Anita; Mieszawska, Aneta J; Hoeben, Freek J M et al. (2013) Synthesis and in vitro evaluation of a multifunctional and surface-switchable nanoemulsion platform. Chem Commun (Camb) 49:9392-4
Cormode, David P; Sanchez-Gaytan, Brenda L; Mieszawska, Aneta J et al. (2013) Inorganic nanocrystals as contrast agents in MRI: synthesis, coating and introduction of multifunctionality. NMR Biomed 26:766-80

Showing the most recent 10 out of 16 publications